A new report from Research and Markets, "Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth,"provides in-depth analysis of the drivers and barriers that affect the global hospital-acquired bacterial infections (HABI) market. The report analyzes the markets for HABI in the U.S., the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and price are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
In 2009, the global hospital acquired bacterial infections market was estimated to be worth $1.8 billion, representing a compound annual growth rate (CAGR) of 1.6 percent between 2001 and 2009. The market is forecast to reach $1.4 billion by 2016, indicating a negative CAGR of 2.9 percent between 2009 and 2016. The primary reason for the reduced growth rate is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2009.
The global hospital-acquired bacterial infections market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs in the urinary tract infections (UTI), pneumonia, surgical site infection (SSI) and bloodstream infection (BSI) markets. The major drugs that are set to lose patent protection include Zyvox (linezolid, 2013), Levaquin (levofloxacin, 2010), Invanz (ertapenem, 2013), Tobi (tobramycin, 2014).
According tot he report, the M&A deals landscape from 2004-2010 suggests that acquisitions are the major deal type accounting for 74 percent of total deals, followed by asset-transactions and mergers accounting for 13 percent each. This signifies that companies are reluctant to invest in anti-bacterial R&D and they prefer acquisition of companies which have developed a new molecule. There is low or zero investment in R&D for anti-bacterials by large pharmaceutical companies because of the small life-cycle of anti-bacterials as resistance is developed against them. So the investment done in R&D for anti-bacterials does not give a good return on investment
The percentage of molecules in the Phase II of development accounts for 66 percent to the total molecules in the pipeline. This is followed by Phase I and filed molecules which accounts for 17 percent each to the total pipeline molecules in the pipeline for HABI.